| Autor: |
Filiz Onat, Eryüksel E, Bulut C, Balcan B, Şengel Be, Tigen Et, Toplu A, Karakurt S, Çulpan Y, Oglu Mgi, Güner A, Gülhan R, Ay P, Patsalos P, Elçi A, Korten, Yildizeli So, Karaalp A, Hasan Raci Yananli, Sili U, Hatipoglu M, Kocakaya D, Ratnaraj N |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.22541/au.162514830.05894749/v1 |
| Popis: |
Favipiravir is one of the repurposed antiviral medications for the treatment of SARS-CoV-2 infection. Since the dosing regimen is a prominent factor for the success of the antiviral therapy, this prospective observational study aimed to characterize the pharmacokinetic characteristics of favipiravir in COVID-19 patients. Adult patients (n=21) hospitalized for mild to moderate COVID-19 with a positive RT-PCR test, and assigned for favipiravir treatment were included. Favipiravir was administered for 5 days, with a loading dose of 3200 mg and a 1200 mg/day maintenance dose. Serial blood samples were collected on Day-2 and Day-4 of the therapy. Laboratory findings of the patients and in-hospital mortality were assessed. Favipiravir concentrations exhibited high variations and a significant decrease during the treatment of COVID-19. The median favipiravir trough concentration (C0-trough) on Day-2 was 21.26 µg/mL whereas it decreased significantly to 1.61 µg/mL on Day-4, the area under the concentration versus time curve decreased from 345.6 µg.h/mL to 108.6 µg.h/mL, respectively. Gender seems significant to affect favipiravir concentrations. Day-2-C0-trough of female patients was significantly higher than male patients. Of the 5 patients that died, 4 were male with a significant increase in ferritin levels from Day-0 to Day-5 compared to surviving patients. In addition, there was a significant decrease in D-dimer and CRP levels in the surviving patients. Our findings indicate that favipiravir concentrations show significant changes during the treatment of COVID-19. Therapeutic drug monitoring may best guide dose adjustments in patients that do not respond to treatment with favipiravir. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
